BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 23721138)

  • 21. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
    Qu X; Huang X; Yan W; Wu L; Dai K
    Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
    Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
    Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
    Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
    Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
    Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
    Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
    Pfannenberg C; Aschoff P; Schanz S; Eschmann SM; Plathow C; Eigentler TK; Garbe C; Brechtel K; Vonthein R; Bares R; Claussen CD; Schlemmer HP
    Eur J Cancer; 2007 Feb; 43(3):557-64. PubMed ID: 17224266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
    Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
    AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study.
    Cafagna D; Rubini G; Iuele F; Maggialetti N; Notaristefano A; Pinto D; Niccoli-Asabella A; Palmiotti G; Lasciarrea M; Maggialetti A
    Radiol Med; 2012 Mar; 117(2):293-311. PubMed ID: 21744252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
    Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
    Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.
    Maggialetti N; Ferrari C; Minoia C; Asabella AN; Ficco M; Loseto G; De Tullio G; de Fazio V; Calabrese A; Guarini A; Rubini G; Brunese L
    Radiol Med; 2016 Feb; 121(2):132-43. PubMed ID: 26349573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan.
    Chatziioannou SN; Georgakopoulos AT; Pianou NK; Kafiri GT; Pavlou SN; Kallergi M
    Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
    Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
    Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI and PET/CT of patients with bone metastases from breast carcinoma.
    Grankvist J; Fisker R; Iyer V; Fründ ET; Simonsen C; Christensen T; Stenbygaard L; Ewertz M; Larsson EM
    Eur J Radiol; 2012 Jan; 81(1):e13-8. PubMed ID: 21227614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
    Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.